So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

A small player like Viking may also win by attracting a partner or even a company that will offer to acquire the biotech.

On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today's highest-growth healthcare markets: weight loss drugs. The biotech ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

Viking Therapeutics has more than one highly promising clinical-stage candidate. It doesn't face much in the way of financial barriers to implementing its strategy. It's also a very appealing partner ...

SAN DIEGO—Matthew Singleton, a director at Viking Therapeutics, Inc. (NASDAQ:VKTX), recently executed a significant stock sale, according to a filing with the Securities and... ByInvesting.com ...

In recent trading, Viking Therapeutics Inc (VKTX) stock price has shown some volatility, fluctuating -6.04% over the last five trades and 9.66% over the past 30 trades. This represents a notable shift ...

Viking aims to compete against market giants Eli Lilly and Novo Nordisk in the billion-dollar weight loss drug market. The biotech recently revealed promising data from trials of its oral weight ...